Brian G.M. Durie, MD is the Chairman of the Board of the International Myeloma Foundation (IMF) as well as Chairman of the IMF’s International Myeloma Working Group (IMWG) and the foundation’s Black Swan Research Initiative®. Dr. Durie is also the Director of Myeloma Research for AMyC Consortium. Dr. Durie, along with Dr. Sydney Salmon, co-created the Durie/Salmon Staging System, which is used worldwide for evaluating patients with myeloma.
Dr. Durie is an attending physician at the Cedars-Sinai Medical Center, with offices located in the Outpatient Cancer Center at the Samuel Oschin Comprehensive Cancer Institute. Previously, he was a professor at the University of Arizona, College of Medicine, and the Charing Cross and Westminster School of Medicine at the University of London.
He is the recipient of numerous honors and awards for excellence. In 2014, he was honored with the Distinguished Alumni Award from Mayo Clinic for his “exceptional contributions” to the field of myeloma. He is a Leukemia Society of America Scholar and a US Hematologic Research Foundation Annual Awardee. Dr. Durie received the 2006 Robert A. Kyle Lifetime Achievement Award, which honors a physician who most exemplifies singular dedication to and compassion for myeloma patients in the search for the best treatment for myeloma. In 2009, Dr. Durie also received the Waldenström’s Award in recognition of his contributions to the field of multiple myeloma.
Dr. Durie has written more than 400 research papers, sixteen book chapters, and five books. He is also an international patent holder for scintillation autoradiography.
Dr. Durie received his medical degree from the University of Edinburgh Medical School, Scotland in 1966. He completed residencies and fellowships at Mayo Clinic and the University of Minnesota. He is board certified by the American Board of Internal Medicine with subspecialties in both medical oncology and hematology.